Interleukin-6 promotes the migration and invasion of nasopharyngeal carcinoma cell lines and upregulates the expression of MMP-2 and MMP-9

Sun,Wei; Liu,Dong-Bo; Li,Wen-Wen; Zhang,Lin-Li; Long,Guo-Xian; Wang,Jun-Feng; Mei,Qi; Hu,Guo-Qing

doi:10.3892/ijo.2014.2323

Interleukin-6 promotes the migration and invasion of nasopharyngeal carcinoma cell lines and upregulates the expression of MMP-2 and MMP-9

Authors:
- Wei Sun
- Dong-Bo Liu
- Wen-Wen Li
- Lin-Li Zhang
- Guo-Xian Long
- Jun-Feng Wang
- Qi Mei
- Guo-Qing Hu
View Affiliations

Affiliations: Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei, Wuhan 430030, P.R. China
Published online on: March 5, 2014 https://doi.org/10.3892/ijo.2014.2323
Pages: 1551-1560

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Nasopharyngeal carcinoma (NPC) shows the highest invasive and metastatic features among head and neck cancers. Distant metastasis remains the predominant mode of treatment failure in NPC patients. The role of interleukin-6 (IL-6) in NPC progression is not fully understood. In this study, we explored whether IL-6 could promote the migration and invasion activity of NPC cell lines, as well as whether the effect of IL-6 on cell migration and invasion is mediated through regulating the expression of matrix metalloproteinase-2 (MMP-2) and MMP-9. Our results revealed that IL-6 and its receptors are broadly expressed in various NPC cell lines including HNE1, HONE1, CNE1, CNE1-LMP1 and 5-8F. Exogenous IL-6 enhanced cell proliferation slightly, but promoted cell migration and invasion significantly in both HNE1 and CNE1-LMP1 cell lines. In addition, an elevation in the expression of MMP-2 and MMP-9 could be induced by IL-6 stimulation. On the contrary, combining treatment with monoclonal anti-human IL-6R antibody (anti-IL-6R mAb) resulted in decreased proliferation, migration and invasion capabilities of NPC cells. Anti-IL-6R mAb also inhibited the expression of MMP-2 and MMP-9 in IL-6-stimulated HNE1 and CNE1-LMP1 cells. In summary, our data suggested that IL-6 mainly promotes the cell migration and invasion of NPC cells. The effect of IL-6 on cell migration and invasion may be mediated through regulation of the expression of MMP-2 and MMP-9. Thus, IL-6 or its related signaling pathways may be a promising target for preventing and inhibiting NPC metastasis.

View Figures

View References

1.	Chan AT: Nasopharyngeal carcinoma. Ann Oncol. 21(Suppl 7): vii308–vii312. 2010.PubMed/NCBI
2.	Wei WI and Mok VW: The management of neck metastases in nasopharyngeal cancer. Curr Opin Otolaryngol Head Neck Surg. 15:99–102. 2007. View Article : Google Scholar : PubMed/NCBI
3.	Huang CJ, Leung SW, Lian SL, Wang CJ, Fang FM and Ho YH: Patterns of distant metastases in nasopharyngeal carcinoma. Kaohsiung J Med Sci. 12:229–234. 1996.PubMed/NCBI
4.	Lee AW, Lin JC and Ng WT: Current management of nasopharyngeal cancer. Semin Radiat Oncol. 22:233–244. 2012. View Article : Google Scholar : PubMed/NCBI
5.	Wang J, Shi M, Hsia Y, et al: Failure patterns and survival in patients with nasopharyngeal carcinoma treated with intensity modulated radiation in Northwest China: a pilot study. Radiat Oncol. 7:22012. View Article : Google Scholar : PubMed/NCBI
6.	Grivennikov SI, Greten FR and Karin M: Immunity, inflammation, and cancer. Cell. 140:883–899. 2010. View Article : Google Scholar
7.	Coussens LM and Werb Z: Inflammation and cancer. Nature. 420:860–867. 2002. View Article : Google Scholar : PubMed/NCBI
8.	Chang CH, Hsiao CF, Yeh YM, et al: Circulating interleukin-6 level is a prognostic marker for survival in advanced nonsmall cell lung cancer patients treated with chemotherapy. Int J Cancer. 132:1977–1985. 2013. View Article : Google Scholar : PubMed/NCBI
9.	Ravishankaran P and Karunanithi R: Clinical significance of preoperative serum interleukin-6 and C-reactive protein level in breast cancer patients. World J Surg Oncol. 9:182011. View Article : Google Scholar : PubMed/NCBI
10.	Schafer ZT and Brugge JS: IL-6 involvement in epithelial cancers. J Clin Invest. 117:3660–3663. 2007. View Article : Google Scholar : PubMed/NCBI
11.	Yanaihara N, Anglesio MS, Ochiai K, et al: Cytokine gene expression signature in ovarian clear cell carcinoma. Int J Oncol. 41:1094–1100. 2012.PubMed/NCBI
12.	Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G and Schaper F: Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J. 374:1–20. 2003. View Article : Google Scholar : PubMed/NCBI
13.	Grivennikov S and Karin M: Autocrine IL-6 signaling: a key event in tumorigenesis? Cancer Cell. 13:7–9. 2008. View Article : Google Scholar : PubMed/NCBI
14.	Yi H, Cho HJ, Cho SM, et al: Blockade of interleukin-6 receptor suppresses the proliferation of H460 lung cancer stem cells. Int J Oncol. 41:310–316. 2012.PubMed/NCBI
15.	Xie G, Yao Q, Liu Y, et al: IL-6-induced epithelial-mesenchymal transition promotes the generation of breast cancer stem-like cells analogous to mammosphere cultures. Int J Oncol. 40:1171–1179. 2012.
16.	Ara T and Declerck YA: Interleukin-6 in bone metastasis and cancer progression. Eur J Cancer. 46:1223–1231. 2010. View Article : Google Scholar : PubMed/NCBI
17.	Kleiner DE and Stetler-Stevenson WG: Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol. 43(Suppl): S42–S51. 1999. View Article : Google Scholar : PubMed/NCBI
18.	Kallakury BV, Karikehalli S, Haholu A, Sheehan CE, Azumi N and Ross JS: Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. Clin Cancer Res. 7:3113–3119. 2001.PubMed/NCBI
19.	Libra M, Scalisi A, Vella N, et al: Uterine cervical carcinoma: role of matrix metalloproteinases (review). Int J Oncol. 34:897–903. 2009. View Article : Google Scholar : PubMed/NCBI
20.	Kurahara S, Shinohara M, Ikebe T, et al: Expression of MMPs, MT-MMP, and TIMPs in squamous cell carcinoma of the oral cavity: correlations with tumor invasion and metastasis. Head Neck. 21:627–638. 1999. View Article : Google Scholar : PubMed/NCBI
21.	Kataoka M, Yamagata S, Takagi H, et al: Matrix metalloproteinase 2 and 9 in esophageal cancer. Int J Oncol. 8:773–779. 1996.PubMed/NCBI
22.	Roomi MW, Monterrey JC, Kalinovsky T, Rath M and Niedzwiecki A: Patterns of MMP-2 and MMP-9 expression in human cancer cell lines. Oncol Rep. 21:1323–1333. 2009.PubMed/NCBI
23.	Roomi MW, Monterrey JC, Kalinovsky T, Rath M and Niedzwiecki A: In vitro modulation of MMP-2 and MMP-9 in human cervical and ovarian cancer cell lines by cytokines, inducers and inhibitors. Oncol Rep. 23:605–614. 2010.
24.	Roomi MW, Monterrey JC, Kalinovsky T, Niedzwiecki A and Rath M: Modulation of MMP-2 and MMP-9 by cytokines, mitogens and inhibitors in lung cancer and malignant mesothelioma cell lines. Oncol Rep. 22:1283–1291. 2009.PubMed/NCBI
25.	Roomi MW, Kalinovsky T, Monterrey J, Rath M and Niedzwiecki A: In vitro modulation of MMP-2 and MMP-9 in adult human sarcoma cell lines by cytokines, inducers and inhibitors. Int J Oncol. 43:1787–1798. 2013.
26.	Kossakowska AE, Edwards DR, Prusinkiewicz C, et al: Interleukin-6 regulation of matrix metalloproteinase (MMP-2 and MMP-9) and tissue inhibitor of metalloproteinase (TIMP-1) expression in malignant non-Hodgkin’s lymphomas. Blood. 94:2080–2089. 1999.PubMed/NCBI
27.	Wang Y, Li L, Guo X, et al: Interleukin-6 signaling regulates anchorage-independent growth, proliferation, adhesion and invasion in human ovarian cancer cells. Cytokine. 59:228–236. 2012. View Article : Google Scholar : PubMed/NCBI
28.	Wang X, Lee SO, Xia S, et al: Endothelial cells enhance prostate cancer metastasis via IL-6→androgen receptor→TGF-β→MMP-9 signals. Mol Cancer Ther. 12:1026–1037. 2013.PubMed/NCBI
29.	Chow KC, Chiou SH, Ho SP, et al: The elevated serum interleukin-6 correlates with the increased serum butyrate level in patients with nasopharyngeal carcinoma. Oncol Rep. 10:813–819. 2003.PubMed/NCBI
30.	Tan EL, Selvaratnam G, Kananathan R and Sam CK: Quantification of Epstein-Barr virus DNA load, interleukin-6, interleukin-10, transforming growth factor-beta1 and stem cell factor in plasma of patients with nasopharyngeal carcinoma. BMC Cancer. 6:2272006. View Article : Google Scholar : PubMed/NCBI
31.	Horikawa T, Yoshizaki T, Sheen TS, Lee SY and Furukawa M: Association of latent membrane protein 1 and matrix metalloproteinase 9 with metastasis in nasopharyngeal carcinoma. Cancer. 89:715–723. 2000. View Article : Google Scholar : PubMed/NCBI
32.	Wong TS, Kwong DL, Sham JS, Wei WI, Kwong YL and Yuen AP: Clinicopathologic significance of plasma matrix metalloproteinase-2 and -9 levels in patients with undifferentiated nasopharyngeal carcinoma. Eur J Surg Oncol. 30:560–564. 2004. View Article : Google Scholar
33.	Liu Z, Li L, Yang Z, et al: Increased expression of MMP9 is correlated with poor prognosis of nasopharyngeal carcinoma. BMC Cancer. 10:2702010. View Article : Google Scholar : PubMed/NCBI
34.	Glaser R, Zhang HY, Yao KT, et al: Two epithelial tumor cell lines (HNE-1 and HONE-1) latently infected with Epstein-Barr virus that were derived from nasopharyngeal carcinomas. Proc Natl Acad Sci USA. 86:9524–9528. 1989. View Article : Google Scholar : PubMed/NCBI
35.	Du CW, Wen BG, Li DR, et al: Latent membrane protein-1 of Epstein-Barr virus increases sensitivity to arsenic trioxide-induced apoptosis in nasopharyngeal carcinoma cell. Exp Oncol. 27:267–272. 2005.PubMed/NCBI
36.	Yan Z, Yong-Guang T, Fei-Jun L, Fa-Qing T, Min T and Ya C: Interference effect of epigallocatechin-3-gallate on targets of nuclear factor kappaB signal transduction pathways activated by EB virus encoded latent membrane protein 1. Int J Biochem Cell Biol. 36:1473–1481. 2004.
37.	Song LB, Yan J, Jian SW, et al: Molecular mechanisms of tumorgenesis and metastasis in nasopharyngeal carcinoma cell sublines. Ai Zheng. 21:158–162. 2002.(In Chinese).
38.	Li J, Fan Y, Chen J, Yao KT and Huang ZX: Microarray analysis of differentially expressed genes between nasopharyngeal carcinoma cell lines 5-8F and 6-10B. Cancer Genet Cytogenet. 196:23–30. 2010.
39.	Chan AT: Current treatment of nasopharyngeal carcinoma. Eur J Cancer. 47(Suppl 3): S302–S303. 2011. View Article : Google Scholar : PubMed/NCBI
40.	Gourzones C, Barjon C and Busson P: Host-tumor interactions in nasopharyngeal carcinomas. Semin Cancer Biol. 22:127–136. 2012. View Article : Google Scholar : PubMed/NCBI
41.	Liao Q, Guo X, Li X, et al: Analysis of the contribution of nasopharyngeal epithelial cancer cells to the induction of a local inflammatory response. J Cancer Res Clin Oncol. 138:57–64. 2012. View Article : Google Scholar : PubMed/NCBI
42.	Chang KP, Chang YT, Wu CC, et al: Multiplexed immuno-bead-based profiling of cytokine markers for detection of nasopharyngeal carcinoma and prognosis of patient survival. Head Neck. 33:886–897. 2011. View Article : Google Scholar : PubMed/NCBI
43.	Eliopoulos AG, Stack M, Dawson CW, et al: Epstein-Barr virus-encoded LMP1 and CD40 mediate IL-6 production in epithelial cells via an NF-kappaB pathway involving TNF receptor-associated factors. Oncogene. 14:2899–2916. 1997. View Article : Google Scholar
44.	Lo AK, Lo KW, Tsao SW, et al: Epstein-Barr virus infection alters cellular signal cascades in human nasopharyngeal epithelial cells. Neoplasia. 8:173–180. 2006. View Article : Google Scholar : PubMed/NCBI
45.	Chen H, Hutt-Fletcher L, Cao L and Hayward SD: A positive autoregulatory loop of LMP1 expression and STAT activation in epithelial cells latently infected with Epstein-Barr virus. J Virol. 77:4139–4148. 2003. View Article : Google Scholar : PubMed/NCBI
46.	Ataie-Kachoie P, Pourgholami MH and Morris DL: Inhibition of the IL-6 signaling pathway: a strategy to combat chronic inflammatory diseases and cancer. Cytokine Growth Factor Rev. 24:163–173. 2013. View Article : Google Scholar : PubMed/NCBI
47.	Weidle UH, Klostermann S, Eggle D and Kruger A: Interleukin 6/interleukin 6 receptor interaction and its role as a therapeutic target for treatment of cachexia and cancer. Cancer Genomics Proteomics. 7:287–302. 2010.PubMed/NCBI
48.	Hsu CP and Chung YC: Influence of interleukin-6 on the invasiveness of human colorectal carcinoma. Anticancer Res. 26:4607–4614. 2006.PubMed/NCBI
49.	Sansone P and Bromberg J: Targeting the interleukin-6/Jak/Stat pathway in human malignancies. J Clin Oncol. 30:1005–1014. 2012. View Article : Google Scholar : PubMed/NCBI
50.	Hudes G, Tagawa ST, Whang YE, et al: A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer. Invest New Drugs. 31:669–676. 2013. View Article : Google Scholar
51.	Guo Y, Nemeth J, O’Brien C, et al: Effects of siltuximab on the IL-6-induced signaling pathway in ovarian cancer. Clin Cancer Res. 16:5759–5769. 2010. View Article : Google Scholar : PubMed/NCBI
52.	Rossi JF, Negrier S, James ND, et al: A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer. Br J Cancer. 103:1154–1162. 2010. View Article : Google Scholar
53.	Hunsucker SA, Magarotto V, Kuhn DJ, et al: Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma. Br J Haematol. 152:579–592. 2011. View Article : Google Scholar : PubMed/NCBI
54.	Voorhees PM, Chen Q, Small GW, et al: Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death. Br J Haematol. 145:481–490. 2009. View Article : Google Scholar : PubMed/NCBI
55.	Voorhees PM, Manges RF, Sonneveld P, et al: A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma. Br J Haematol. 161:357–366. 2013. View Article : Google Scholar : PubMed/NCBI
56.	Shinriki S, Jono H, Ota K, et al: Humanized anti-interleukin-6 receptor antibody suppresses tumor angiogenesis and in vivo growth of human oral squamous cell carcinoma. Clin Cancer Res. 15:5426–5434. 2009. View Article : Google Scholar : PubMed/NCBI
57.	Kudo M, Jono H, Shinriki S, et al: Antitumor effect of humanized anti-interleukin-6 receptor antibody (tocilizumab) on glioma cell proliferation. Laboratory investigation. J Neurosurg. 111:219–225. 2009. View Article : Google Scholar : PubMed/NCBI
58.	Yoshio-Hoshino N, Adachi Y, Aoki C, Pereboev A, Curiel DT and Nishimoto N: Establishment of a new interleukin-6 (IL-6) receptor inhibitor applicable to the gene therapy for IL-6-dependent tumor. Cancer Res. 67:871–875. 2007. View Article : Google Scholar : PubMed/NCBI
59.	Hsu CP, Chen YL, Huang CC, et al: Anti-interleukin-6 receptor antibody inhibits the progression in human colon carcinoma cells. Eur J Clin Invest. 41:277–284. 2011. View Article : Google Scholar : PubMed/NCBI